Drug Trial Radar · NCT04313023
The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2
Last checked: Nov 19, 2026Latest source record: May 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
217
Actual
Start
Jun 9, 2020
Primary completion
Jul 31, 2021
Study completion Jul 31, 2021
Sponsor
- Lead sponsor
- Pulmotect, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- United States Department of Defense
- First posted
- Mar 18, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Subjects who have documented exposure to SARS-CoV-2 (COVID-19) will receive 4 doses of PUL-042 Inhalation Solution or 4 doses of a placebo solution by inhalation over 10 days. Subjects will be followed for the incidence and severity of COVID-19 over 28 days. Subjects will be tested for infection with SARS-CoV-2 at the beginning, middle and end of the study.
Conditions
- COVID-19
Interventions
PUL-042 Inhalation SolutionDrug
20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042) PUL-042 Inhalation Solution
PlaceboDrug
Sterile saline for inhalation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Severity of COVID-19: Evaluation of the Severity of COVID-19 as Measured by the Maximum Difference From the Baseline Value in the OSCI Within 28 Days From the Start of Experimental Therapy.Time frame: 28 days
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
University of California Irvine
Orange, California
Premier Urgent Care of California
San Bernardino, California
Clinical Research of South Florida Alliance for Multispecialty Research
Coral Gables, Florida
Invesclinic US LLC
Fort Lauderdale, Florida
Luminous Cinical Research- South Florida Urgent Care
Miami, Florida
Entrust Clinical Research
Miami, Florida
DBC Research
Tamarac, Florida
Affinity Clinical Research, LLC
Tampa, Florida
Clinical Research Atlanta
Stockbridge, Georgia
Willis-Knighton Physcian Network
Bossier City, Louisiana
Ascension St John
Bartlesville, Oklahoma
Ascension St. John
Tulsa, Oklahoma
Invesclinic US LLC
Edinburg, Texas
MD Anderson Cancer Center
Houston, Texas
Next Level Urgent Care
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.